Skip Navigation



Annals of Oncology Advance Access published online on March 28, 2008
Annals of Oncology, doi:10.1093/annonc/mdn152
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/6/1203    most recent
mdn152v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Harputluoglu, H.
Right arrow Articles by Altundag, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harputluoglu, H.
Right arrow Articles by Altundag, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letter to the editor

How can we use anthracylines in the management of newly diagnosed metastatic breast cancer patients overexpressing HER-2?

The first 10% of the full text of this article appears below.

Most women who have metastatic breast cancer (MBC) have had early-stage breast cancer. Therefore, many of them received adjuvant treatment including anthracylines. Starting off . . . [Full Text of this Article]

H. Harputluoglu and K. Altundag*

Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey

* (E-mail: altundag66@yahoo.com)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?